{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations after 12 cycles of treatment.\n\nCriteria for CR, nCR, VGPR and PR are defined in prior outcomes.","groups":[{"description":"Bortezomib 1.3mg/m\\^2 by IV days 1, 4, 8 \\& 11\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO days 1-4, 9-12, 17-20","id":"OG000","title":"CyBorD (Bortezomib 1.3mg/m^2)"},{"description":"Bortezomib 1.5mg/m\\^2 by IV days 1, 8, 15 \\& 22\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 \\& 22","id":"OG001","title":"CyBorD (Bortezomib 1.5mg/m^2)"}],"paramType":"NUMBER","populationDescription":"No participants received 12 cycles of treatment; therefore, all participants are non-evalualble.","reportingStatus":"POSTED","timeFrame":"After 12 cycles of treatment","title":"Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 12 Cycles","type":"SECONDARY","unitOfMeasure":"participants"}